Skip to main content

Table 1 Patient baseline characteristics

From: Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study

Male/female sex n (%) 68/48 (59%/41%)
Age [median (range)] 51 (22–80)
HCV subtype n (%)1a/1b/1a + b 34/77/5 (29%/67%/4%)
HCV-RNA level [median (IQR)] copies/mL 1.8 × 106 (4.5 × 105–6.2 × 106)
AST [median (IQR)] U/L 44 (32–73)
ALT [median (IQR)] U/L 51 (32–93)
γ-GT [median (IQR)] U/L 50 (28–100)
Vitamin B12 [median (IQR)] ng/L 488 (339–727)
Hepatitis activity n (%)
 Mild 79 (68%)
 Moderate/severe 37 (32%)
Fibrosis n (%)
 Absent/mild/moderate 89 (77%)
 Severe/cirrhosis 27 (23%)
Steatosis n (%)
 0–5% 58 (50%)
 6–100% 57 (49%)
 Missing 1 (1%)
IFNL3/IFNL4 rs12979860 n (%)
 CC 44 (38%)
 CT 54 (47%)
 TT 14 (12%)
 Missing 4 (3%)
  1. Laboratory data are presented as mean and interquartile (IQR); number of cases are given in total and as a percentage; Baseline serum vitamin B12 levels were available for 107 patients.
\